Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Vaccines01:30

Cancer Vaccines

870
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Unmet needs in penile cancer: Review and perspectives from the Global Society of Rare Genitourinary Tumors.

Urologic oncology·2026
Same author

Evaluation of the Feasibility and Safety of Ifosfamide-Based Chemotherapy Regimens for Sarcomas in the Outpatient Setting.

JCO oncology practice·2026
Same author

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026

Related Experiment Video

Updated: Dec 22, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K

Effective combinatorial immunotherapy for penile squamous cell carcinoma.

Tianhe Huang1,2,3, Xi Cheng1,2,4, Jad Chahoud5

  • 1Department of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, 46556, USA.

Nature Communications
|May 3, 2020
PubMed
Summary

A new mouse model for penile squamous cell carcinoma (PSCC) reveals an immunosuppressive tumor microenvironment. Combining immune checkpoint blockade with specific drugs shows promise for treating this understudied cancer.

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Related Experiment Videos

Last Updated: Dec 22, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.1K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.0K

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Penile squamous cell carcinoma (PSCC) is a significant health concern, particularly in developing nations.
  • The lack of adequate laboratory models hinders research into PSCC's molecular mechanisms and therapeutic strategies.
  • Understanding PSCC's biology is crucial for improving patient outcomes.

Purpose of the Study:

  • To develop a genetically engineered mouse model for studying penile squamous cell carcinoma (PSCC).
  • To investigate the tumor microenvironment and identify therapeutic targets in PSCC.
  • To establish a preclinical platform for evaluating novel PSCC treatment strategies.

Main Methods:

  • Co-deletion of Smad4 and Apc genes in the androgen-responsive mouse penis epithelium to create a PSCC model.
  • Characterization of the tumor microenvironment, focusing on myeloid-derived suppressor cells (MDSCs).
  • Preclinical evaluation of therapeutic interventions, including immune checkpoint blockade and MDSC-targeting drugs (cabozantinib, celecoxib).
  • Investigation of cisplatin chemoresistance mechanisms, particularly in the context of Pten deficiency.

Main Results:

  • The developed mouse model successfully recapitulates key features of human PSCC.
  • PSCC tumors exhibit an immunosuppressive microenvironment dominated by MDSCs.
  • Combination therapy of immune checkpoint blockade with cabozantinib or celecoxib demonstrated synergistic efficacy.
  • Pten deficiency was identified as a driver of cisplatin chemoresistance in this model.
  • Drug screening and proteomics identified potential therapeutic avenues for PSCC.

Conclusions:

  • The genetically engineered mouse model serves as a valuable resource for PSCC research.
  • Targeting the immunosuppressive tumor microenvironment, particularly MDSCs, is a promising therapeutic strategy for PSCC.
  • Understanding chemoresistance mechanisms is critical for developing effective PSCC treatments.
  • This study provides essential tools and insights for advancing PSCC biology and therapy development.